Bong Jun Woo, Kang Sanghee, Park Pyoungjae
Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Ann Surg Treat Res. 2023 Nov;105(5):271-280. doi: 10.4174/astr.2023.105.5.271. Epub 2023 Oct 31.
PURPOSE: The role of paraaortic lymph node dissection (PALND) in colorectal cancer (CRC) has been less evaluated than surgical treatments for other distant metastases. We evaluated surgical outcomes after PALND and identified prognostic factors. METHODS: The medical records of patients who underwent PALND for paraaortic lymph node metastasis (PALNM) were reviewed retrospectively. All patients were categorized into the M1a group (isolated PALNM, n = 27), and the M1bc group (distant metastases other than PALNM, n = 26). Three severity factors (PALNM-SF: number of harvested paraaortic lymph nodes [hLN], ≥14; number of metastatic paraaortic lymph nodes [mLN], ≥5; and lymph nodes ratio [mLN/hLN], ≥0.5) were defined to determine their effects on survival. RESULTS: The 5-year overall survival (OS) of the M1a and M1bc groups were 61.1% and 6.4%, respectively (P = 0.0013). The 5-year disease-free survival (DFS) of the M1a group was 47.4%, and the 3-year DFS of the M1bc group was 9.1% (P < 0.001). Patients with 2 or more PALNM-SFs showed worse OS than those with 1 PALNM-SF (P = 0.017). In multivariate analysis, M1bc (non-isolated PALNM) was the only significant factor for survival. In the M1a group, patients with 2 or more PALNM-SFs showed significantly worse survival than those with a single PALNM-SF. In multivariate analysis, 2 or more PALNM-SF was a significant factor for survival. CONCLUSION: PALND for CRC provided favorable outcomes in the survival of an isolated PALNM, although this was uncertain for non-isolated PALNMs. The PALNM-SFs helped assess the prognosis after PALND.
目的:与针对其他远处转移的手术治疗相比,腹主动脉旁淋巴结清扫术(PALND)在结直肠癌(CRC)中的作用评估较少。我们评估了PALND后的手术结果并确定了预后因素。 方法:回顾性分析因腹主动脉旁淋巴结转移(PALNM)接受PALND的患者的病历。所有患者分为M1a组(孤立性PALNM,n = 27)和M1bc组(除PALNM外的远处转移,n = 26)。定义了三个严重程度因素(PALNM-SF:腹主动脉旁淋巴结收获数[hLN],≥14;腹主动脉旁转移淋巴结数[mLN],≥5;以及淋巴结比率[mLN/hLN],≥0.5)以确定它们对生存的影响。 结果:M1a组和M1bc组的5年总生存率(OS)分别为61.1%和6.4%(P = 0.0013)。M1a组的5年无病生存率(DFS)为47.4%,M1bc组的3年DFS为9.1%(P < 0.001)。具有2个或更多PALNM-SF的患者的OS比具有1个PALNM-SF的患者更差(P = 0.017)。在多变量分析中,M1bc(非孤立性PALNM)是生存的唯一显著因素。在M1a组中,具有2个或更多PALNM-SF的患者的生存率明显低于具有单个PALNM-SF的患者。在多变量分析中,2个或更多PALNM-SF是生存的显著因素。 结论:CRC的PALND在孤立性PALNM的生存方面提供了良好的结果,尽管对于非孤立性PALNM来说这并不确定。PALNM-SF有助于评估PALND后的预后。
World J Gastrointest Oncol. 2021-9-15
PLoS One. 2020-10-12
World J Surg Oncol. 2020-8-28
Ann Surg Treat Res. 2019-7